Advertisement
Screener

ENANTA PHARMACEUTICALS, INC (ENTA) Payments to Acquire Marketable Securities

1.6 / 5 stars · 38/120 Roast Me

ENANTA PHARMACEUTICALS, INC Payments to Acquire Marketable Securities

ENANTA PHARMACEUTICALS, INC (ENTA) reported Payments to Acquire Marketable Securities of $216.08 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-12

  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2026-06-30 was $25.51M, a 70.33% decline year-over-year.
  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2026-03-31 was $41.95M, a 23.75% decline year-over-year.
  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2025-12-31 was $148.62M.
  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for the quarter ending 2025-09-30 was $68.62M.
  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2025 was $209.63M, a 31.78% decline from fiscal 2024.
  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2024 was $307.28M, a 17.71% decline from fiscal 2023.
  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2023 was $373.39M, a 117.79% increase from fiscal 2022.
  • ENANTA PHARMACEUTICALS, INC payments to acquire marketable securities for fiscal 2022 was $171.45M, a 44.22% decline from fiscal 2021.
Period endPayments to Acquire Marketable Securities 3 monthPayments to Acquire Marketable Securities 6 monthPayments to Acquire Marketable Securities 9 monthPayments to Acquire Marketable Securities 12 month
2026-06-30$25.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12
$67.46M
derived: sum of 2 quarters · filed 2026-08-12
$216.08M
10-Q · filed 2026-08-12
$284.70M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$41.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13
$190.57M
10-Q · filed 2026-05-13
$259.19M
derived: sum of 3 quarters · filed 2026-05-13
$345.19M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$148.62M
10-Q · filed 2026-02-11
$217.25M
derived: sum of 2 quarters · filed 2026-02-11
$303.24M
derived: sum of 3 quarters · filed 2026-08-12
$358.25M
derived: sum of 4 quarters · filed 2026-08-12
2025-09-30$68.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19
$154.61M
derived: sum of 2 quarters · filed 2026-08-12
$209.63M
derived: sum of 3 quarters · filed 2026-08-12
$209.63M
10-K · filed 2025-11-19
2025-06-30$85.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12
$141.01M
derived: sum of 2 quarters · filed 2026-08-12
$141.01M
10-Q · filed 2026-08-12
$141.01M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$55.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13
$55.02M
10-Q · filed 2026-05-13
$55.02M
derived: sum of 3 quarters · filed 2026-05-13
$150.16M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$0.00
10-Q · filed 2026-02-11
-$1.00K
derived: sum of 2 quarters · filed 2026-02-11
$95.15M
derived: sum of 3 quarters · filed 2026-02-11
$160.44M
derived: sum of 4 quarters · filed 2026-02-11
2024-09-30-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19
$95.15M
derived: sum of 2 quarters · filed 2025-11-19
$160.44M
derived: sum of 3 quarters · filed 2025-11-19
$307.28M
10-K · filed 2025-11-19
2024-06-30$95.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13
$160.44M
derived: sum of 2 quarters · filed 2025-08-13
$307.28M
10-Q · filed 2025-08-13
$413.40M
derived: sum of 4 quarters · filed 2025-11-19
2024-03-31$65.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14
$212.13M
10-Q · filed 2025-05-14
$318.25M
derived: sum of 3 quarters · filed 2025-11-19
$494.90M
derived: sum of 4 quarters · filed 2025-11-19
2023-12-31$146.84M
10-Q · filed 2025-02-12
$252.96M
derived: sum of 2 quarters · filed 2025-11-19
$429.61M
derived: sum of 3 quarters · filed 2025-11-19
$452.86M
derived: sum of 4 quarters · filed 2025-11-19
2023-09-30$106.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19
$282.76M
derived: sum of 2 quarters · filed 2025-11-19
$306.02M
derived: sum of 3 quarters · filed 2025-11-19
$373.39M
10-K · filed 2025-11-19
2023-06-30$176.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07
$199.90M
derived: sum of 2 quarters · filed 2024-08-07
$267.27M
10-Q · filed 2024-08-07
$276.01M
derived: sum of 4 quarters · filed 2024-11-27
2023-03-31$23.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08
$90.63M
10-Q · filed 2024-05-08
$99.36M
derived: sum of 3 quarters · filed 2024-11-27
$137.44M
derived: sum of 4 quarters · filed 2024-11-27
2022-12-31$67.38M
10-Q · filed 2024-02-08
$76.11M
derived: sum of 2 quarters · filed 2024-11-27
$114.19M
derived: sum of 3 quarters · filed 2024-11-27
$175.92M
derived: sum of 4 quarters · filed 2024-11-27
2022-09-30$8.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27
$46.81M
derived: sum of 2 quarters · filed 2024-11-27
$108.54M
derived: sum of 3 quarters · filed 2024-11-27
$171.45M
10-K · filed 2024-11-27
2022-06-30$38.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08
$99.81M
derived: sum of 2 quarters · filed 2023-08-08
$162.71M
10-Q · filed 2023-08-08
$162.11M
derived: sum of 4 quarters · filed 2023-11-22
2022-03-31$61.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-09
$124.63M
10-Q · filed 2023-05-09
$124.03M
derived: sum of 3 quarters · filed 2023-11-22
$260.39M
derived: sum of 4 quarters · filed 2023-11-22
2021-12-31$62.90M
10-Q · filed 2023-02-08
$62.30M
derived: sum of 2 quarters · filed 2023-11-22
$198.66M
derived: sum of 3 quarters · filed 2023-11-22
$265.58M
derived: sum of 4 quarters · filed 2023-11-22
2021-09-30-$601.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-22
$135.76M
derived: sum of 2 quarters · filed 2023-11-22
$202.67M
derived: sum of 3 quarters · filed 2023-11-22
$307.35M
10-K · filed 2023-11-22
2021-06-30$136.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08
$203.28M
derived: sum of 2 quarters · filed 2022-08-08
$307.95M
10-Q · filed 2022-08-08
$378.92M
derived: sum of 4 quarters · filed 2022-11-23
2021-03-31$66.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-09
$171.59M
10-Q · filed 2022-05-09
$242.55M
derived: sum of 3 quarters · filed 2022-11-23
$338.25M
derived: sum of 4 quarters · filed 2022-11-23
2020-12-31$104.67M
10-Q · filed 2022-02-10
$175.64M
derived: sum of 2 quarters · filed 2022-11-23
$271.34M
derived: sum of 3 quarters · filed 2022-11-23
$325.77M
derived: sum of 4 quarters · filed 2022-11-23
2020-09-30$70.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23
$166.67M
derived: sum of 2 quarters · filed 2022-11-23
$221.09M
derived: sum of 3 quarters · filed 2022-11-23
$338.55M
10-K · filed 2022-11-23
2020-06-30$95.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09
$150.13M
derived: sum of 2 quarters · filed 2021-08-09
$267.59M
10-Q · filed 2021-08-09
$463.52M
derived: sum of 4 quarters · filed 2021-11-24
2020-03-31$54.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-10
$171.88M
10-Q · filed 2021-05-10
$367.81M
derived: sum of 3 quarters · filed 2021-11-24
$449.48M
derived: sum of 4 quarters · filed 2021-11-24
2019-12-31$117.46M
10-Q · filed 2021-02-09
$313.39M
derived: sum of 2 quarters · filed 2021-11-24
$395.06M
derived: sum of 3 quarters · filed 2021-11-24
$547.23M
derived: sum of 4 quarters · filed 2021-11-24
2019-09-30$195.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24
$277.60M
derived: sum of 2 quarters · filed 2021-11-24
$429.77M
derived: sum of 3 quarters · filed 2021-11-24
$549.31M
10-K · filed 2021-11-24
2019-06-30$81.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10
$233.84M
derived: sum of 2 quarters · filed 2020-08-10
$353.38M
10-Q · filed 2020-08-10
$467.41M
derived: sum of 4 quarters · filed 2020-11-25
2019-03-31$152.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11
$271.71M
10-Q · filed 2020-05-11
$385.74M
derived: sum of 3 quarters · filed 2020-11-25
$465.09M
derived: sum of 4 quarters · filed 2020-11-25
2018-12-31$119.55M
10-Q · filed 2020-02-10
$233.57M
derived: sum of 2 quarters · filed 2020-11-25
$312.93M
derived: sum of 3 quarters · filed 2020-11-25
$357.94M
derived: sum of 4 quarters · filed 2020-11-25
2018-09-30$114.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25
$193.38M
derived: sum of 2 quarters · filed 2020-11-25
$238.39M
derived: sum of 3 quarters · filed 2020-11-25
$293.10M
10-K · filed 2020-11-25
2018-06-30$79.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09
$124.37M
derived: sum of 2 quarters · filed 2019-08-09
$179.08M
10-Q · filed 2019-08-09
$244.22M
derived: sum of 4 quarters · filed 2019-11-27
2018-03-31$45.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10
$99.72M
10-Q · filed 2019-05-10
$164.87M
derived: sum of 3 quarters · filed 2019-11-27
$199.82M
derived: sum of 4 quarters · filed 2019-11-27
2017-12-31$54.71M
10-Q · filed 2019-02-08
$119.86M
derived: sum of 2 quarters · filed 2019-11-27
$154.81M
derived: sum of 3 quarters · filed 2019-11-27
$232.41M
derived: sum of 4 quarters · filed 2019-11-27
2017-09-30$65.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27
$100.10M
derived: sum of 2 quarters · filed 2019-11-27
$177.70M
derived: sum of 3 quarters · filed 2019-11-27
$251.37M
10-K · filed 2019-11-27
2017-06-30$34.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-09
$112.55M
derived: sum of 2 quarters · filed 2018-08-09
$186.22M
10-Q · filed 2018-08-09
$228.16M
derived: sum of 4 quarters · filed 2018-11-29
2017-03-31$77.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10
$151.27M
10-Q · filed 2018-05-10
$193.21M
derived: sum of 3 quarters · filed 2018-11-29
$259.14M
derived: sum of 4 quarters · filed 2018-11-29
2016-12-31$73.67M
10-Q · filed 2018-02-09
$115.61M
derived: sum of 2 quarters · filed 2018-11-29
$181.54M
derived: sum of 3 quarters · filed 2018-11-29
$231.48M
derived: sum of 4 quarters · filed 2018-11-29
2016-09-30$41.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29
$107.87M
derived: sum of 2 quarters · filed 2018-11-29
$157.81M
derived: sum of 3 quarters · filed 2018-11-29
$192.43M
10-K · filed 2018-11-29
2016-06-30$65.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09
$115.87M
derived: sum of 2 quarters · filed 2017-08-09
$150.49M
10-Q · filed 2017-08-09
$191.21M
derived: sum of 4 quarters · filed 2017-12-11
2016-03-31$49.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10
$84.56M
10-Q · filed 2017-05-10
$125.28M
derived: sum of 3 quarters · filed 2017-12-11
$145.03M
derived: sum of 4 quarters · filed 2017-12-11
2015-12-31$34.62M
10-Q · filed 2017-02-09
$75.34M
derived: sum of 2 quarters · filed 2017-12-11
$95.09M
derived: sum of 3 quarters · filed 2017-12-11
$222.77M
derived: sum of 4 quarters · filed 2017-12-11
2015-09-30$40.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11
$60.47M
derived: sum of 2 quarters · filed 2017-12-11
$188.15M
derived: sum of 3 quarters · filed 2017-12-11
$196.30M
10-K · filed 2017-12-11
2015-06-30$19.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09
$147.43M
derived: sum of 2 quarters · filed 2016-08-09
$155.58M
10-Q · filed 2016-08-09
$168.24M
derived: sum of 4 quarters · filed 2016-12-09
2015-03-31$127.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10
$135.83M
10-Q · filed 2016-05-10
$148.49M
derived: sum of 3 quarters · filed 2016-12-09
$209.66M
derived: sum of 4 quarters · filed 2016-12-09
2014-12-31$8.15M
10-Q · filed 2016-02-09
$20.81M
derived: sum of 2 quarters · filed 2016-12-09
$81.99M
derived: sum of 3 quarters · filed 2016-12-09
$96.34M
derived: sum of 4 quarters · filed 2016-12-09
2014-09-30$12.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09
$73.83M
derived: sum of 2 quarters · filed 2016-12-09
$88.18M
derived: sum of 3 quarters · filed 2016-12-09
$98.41M
10-K · filed 2016-12-09
2014-06-30$61.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10
$75.53M
derived: sum of 2 quarters · filed 2015-08-10
$85.75M
10-Q · filed 2015-08-10
$101.39M
derived: sum of 4 quarters · filed 2015-12-11
2014-03-31$14.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-08
$24.57M
10-Q · filed 2015-05-08
$40.21M
derived: sum of 3 quarters · filed 2015-12-11
$94.75M
derived: sum of 4 quarters · filed 2015-12-11
2013-12-31$10.22M
10-Q · filed 2015-02-06
$25.86M
derived: sum of 2 quarters · filed 2015-12-11
$80.40M
derived: sum of 3 quarters · filed 2015-12-11
$112.97M
derived: sum of 4 quarters · filed 2015-12-11
2013-09-30$15.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11
$70.18M
derived: sum of 2 quarters · filed 2015-12-11
$102.75M
derived: sum of 3 quarters · filed 2015-12-11
$115.89M
10-K · filed 2015-12-11
2013-06-30$54.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12
$87.11M
derived: sum of 2 quarters · filed 2014-08-12
$100.25M
10-Q · filed 2014-08-12
$101.70M
derived: sum of 4 quarters · filed 2014-12-11
2013-03-31$32.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12
$45.71M
10-Q · filed 2014-05-12
$47.15M
derived: sum of 3 quarters · filed 2014-12-11
$63.85M
derived: sum of 4 quarters · filed 2014-12-11
2012-12-31$13.14M
10-Q · filed 2014-02-13
$14.59M
derived: sum of 2 quarters · filed 2014-12-11
$31.29M
derived: sum of 3 quarters · filed 2014-12-11
2012-09-30$1.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11
$18.14M
derived: sum of 2 quarters · filed 2014-12-11
$47.69M
10-K · filed 2014-12-11
2012-06-30$16.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12
$46.25M
10-Q · filed 2013-08-12
2012-03-31$29.55M
10-Q · filed 2013-05-15
2011-09-30$33.57M
10-K · filed 2013-12-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Rezolute, Inc. (RZLT)United States$0.382B-6.45
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63